Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

NCT03507998 is registered in ClinicalTrials.gov with Curegenix Inc. as lead sponsor.

NCT NCT03507998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03507998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
Lead sponsor
Curegenix Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
June 17, 2017
Completion date
April 1, 2021
Enrollment
39 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct carcinoma, colorectal adenocarcinoma, esophageal carcinoma, gastric adenocarcinoma, gastrointestinal cancer, hepatocellular carcinoma, pancreatic adenocarcinoma